Toggle Main Menu Toggle Search

Open Access padlockePrints

Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma

Lookup NU author(s): Dr Maria Lastowska, Dr Michael Jackson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Overexpression of the human MYCN oncogene driven by a tyrosine hydroxylase promoter causes tumours in transgenic mice that recapitulate the childhood cancer neuroblastoma. To establish an in vitro model to study this process, a series of isogenic cell lines were developed from these MYCN-driven murine tumours. Lines were established from tumours arising in homozygous and hemizygous MYCN transgenic mice. Hemizygous tumours gave rise to cell lines growing only in suspension. Homozygous tumours gave rise to similar suspension lines as well as morphologically distinct substrate-adherent lines characteristic of human S-type neuroblastoma cells. FISH analysis demonstrated selective MYCN transgene amplification in cell lines derived from hemizygous mice. Comparative genomic hybridisation (CGH) and fluorescence in situ hybridisation (FISH) analysis confirmed a range of neuroblastoma-associated genetic changes in the various lines, in particular, gain of regions syntenic with human 17q. These isogenic lines together with the transgenic mice thus represent valuable models for investigating the biological characteristics of aggressive neuroblastoma. © 2007 Elsevier Ltd. All rights reserved.


Publication metadata

Author(s): Cheng AJ, Ching Cheng N, Ford J, Smith J, Murray JE, Flemming C, Lastowska M, Jackson MS, Hackett CS, Weiss WA, Marshall GM, Kees UR, Norris MD, Haber M

Publication type: Article

Publication status: Published

Journal: European Journal of Cancer

Year: 2007

Volume: 43

Issue: 9

Pages: 1467-1475

Print publication date: 01/06/2007

ISSN (print): 0959-8049

ISSN (electronic): 1879-0852

Publisher: Pergamon

URL: http://dx.doi.org/10.1016/j.ejca.2007.03.008

DOI: 10.1016/j.ejca.2007.03.008

PubMed id: 17449239


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
K02 NS002226NINDS NIH HHS
K02NS02226-05NINDS NIH HHS
R01 CA102321-04A1NCI NIH HHS
R01 CA102321-05NCI NIH HHS
R01 CA102321-06NCI NIH HHS
R01 CA102321-07NCI NIH HHS
R01 NS055750-01A2S1NINDS NIH HHS
R01 NS055750-02NINDS NIH HHS
R01CAA102321PHS HHS
R01 CA102321NCI NIH HHS
R01 CA102321-08NCI NIH HHS
R01 NS055750NINDS NIH HHS
R01 NS055750-01A2NINDS NIH HHS
R01 NS055750-02S1NINDS NIH HHS
R01 NS055750-03NINDS NIH HHS
R01 NS055750-04NINDS NIH HHS

Share